Krebs, Fanny S.
Britschgi, Christian
Pradervand, Sylvain
Achermann, Rita
Tsantoulis, Petros
Haefliger, Simon
Wicki, Andreas
Michielin, Olivier
Zoete, Vincent
Article History
Received: 17 December 2021
Accepted: 12 July 2022
First Online: 22 July 2022
Competing interests
: V.Z. is a consultant for Cellestia Biotech. O.M. is the beneficiary of research funding from Merck Sharp & Dohme, Bristol-Myers Squibb, and Roche and/or is a consultant or participated to advisory boards for Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb, Amgen, Roche, and GlaxoSmithKline. F.S.K., C.B., S.P., R.A., P.T., S.H. and A.W. declare no competing interest.